Abstract
Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PETs unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.
Keywords: Radiolabelled Tracers, Anticancer Drugs, Positron Emission Tomography pet, anti cancer therapy, anticancer angents, n dihmethylamino ethyl acridine carboxamide, temozolomide, f fdg, c thymidine, muti drug resistance mdr, hypoxia
Current Pharmaceutical Design
Title: Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET
Volume: 7 Issue: 18
Author(s): Frank Brady, Sajinder K. Luthra, Gavin D. Brown, Safiye Osman, Eric Aboagye, Azeem Saleem and Patricia M. Price
Affiliation:
Keywords: Radiolabelled Tracers, Anticancer Drugs, Positron Emission Tomography pet, anti cancer therapy, anticancer angents, n dihmethylamino ethyl acridine carboxamide, temozolomide, f fdg, c thymidine, muti drug resistance mdr, hypoxia
Abstract: Positron Emission Tomography (PET) has the potential to improve efficacy of established and novel cancer therapies and to assist more rapid and rational progression of promising novel therapies into the clinic. This is due to PETs unrivalled sensitivity and ability to monitor the pharmacokinetics and pharmacodynamics of drugs and biochemicals radiolabelled with short -lived positron emitting radioisotopes. PET is a multidisciplinary science which employs chemists, biologists, mathematicial modellers, pharmacologists as well as clinicians. Clinical research questions in oncology determine the methodological challenges faced by these other disciplines. Within this context we focus on the developments of the radiolabelled compounds that have underpinned the clinical work in oncology for monitoring tumour and normal tissue pharmacokinetics, assessment of tumour response, cell proliferation, gene expression, hypoxia, multidrug resistance and status of receptors on tumours.
Export Options
About this article
Cite this article as:
Brady Frank, Luthra K. Sajinder, Brown D. Gavin, Osman Safiye, Aboagye Eric, Saleem Azeem and Price M. Patricia, Radiolabelled Tracers and Anticancer Drugs for Assessment of Therapeutic Efficacy Using PET, Current Pharmaceutical Design 2001; 7 (18) . https://dx.doi.org/10.2174/1381612013396907
DOI https://dx.doi.org/10.2174/1381612013396907 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pre-viable Newborns in Saudi Arabia: Where are We Now and What the Future May Hold?
Current Pediatric Reviews Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design Editorial (Cellular Senescence and Inflammation: Advances and Therapeutic Targets in Aging and Major Age-Related Diseases)
Current Pharmaceutical Design Kaempferol Improves TRAIL-Mediated Apoptosis in Leukemia MOLT-4 Cells by the Inhibition of Anti-apoptotic Proteins and Promotion of Death Receptors Expression
Anti-Cancer Agents in Medicinal Chemistry Retinoids in Cancer Chemoprevention
Current Cancer Drug Targets Near-Infrared Quantum Dots as Optical Probes for Tumor Imaging
Current Topics in Medicinal Chemistry Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Editorial [Hot Topic:Food-Derived Bioactive Proteins and Peptides as Potential Components of Nutraceuticals (Executive Editor: H. Meisel)]
Current Pharmaceutical Design Editorial (Thematic Issue: Signalling Pathways in Anti-cancer Drug Resistance)
Current Medicinal Chemistry Carbon Nanofiber Reinforced Polycaprolactone Fibrous Meshes by Electrostatic Co-spinning
Current Nanoscience Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Analytical Tools for Detecting Amyloid Beta Oligomerisation and Assembly
Current Pharmaceutical Analysis Genetic Databases and their Potential in Pharmacogenomics
Current Pharmaceutical Design Roles of Type 10 17beta-Hydroxysteroid Dehydrogenase in Intracrinology and Metabolism of Isoleucine and Fatty Acids
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Oxidative Stress and Anti-Oxidant Treatment in Platinum- Induced Peripheral Neurotoxicity
Current Cancer Drug Targets Editorial (Thematic Issue: The Lung and Winding Road: Twists and Turns on the Way to Personalized NSCLC Therapy)
Current Pharmaceutical Design Editorial [Hot Topic :Current Advances In Therapeutic Applications of Nuclear Receptors (Guest Editor: Stefano Fiorucci)]
Current Topics in Medicinal Chemistry Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Translational Optical Imaging in Diagnosis and Treatment of Cancer
Current Pharmaceutical Biotechnology